Author:
Bode C.,Peter K.,Runge M. S.,Haber E.
Publisher
Springer Berlin Heidelberg
Reference66 articles.
1. Adgey AA (1998) An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Eur Heart J 19 [Suppl D]:D10–D21
2. AIMS Trial Study Group (1988) Effect of intravenous APSAC on mortality after acute myocardial infarction. Preliminary report of a placebo-controlled clinical trial. Lancet 1:545–549
3. Bates SM, Weitz JI (1999) Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin. Cardiovasc Res 41:418–432
4. Bode C, Hanson SR, Schmedtje JF Jr, Haber E, Mehwald P, Kelly AB, Harker LA, Runge MS (1997) Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting. Circulation 95:800–804
5. Bode C, Hudelmayer M, Mehwald P, Bauer S, Freitag M, von Hodenberg E, Newell JB, Kübler W, Haber E, Runge MS (1994) Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. Circulation 90:1956–1963